News MIT team develops 'years-long' drug delivery tech Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.
News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News Supernus reports less than super data for depression drug Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.
News J&J's Spravato gets another lift with new FDA approval Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
News Boehringer drug for brain fog in schizophrenia fails trial Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.
Patients Keeping stigma out of it: Personalising the mental health co... Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.
Market Access Sanofi's Dupixent gets FDA nod for chronic hives indication Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl